LC-MS/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors.
暂无分享，去创建一个
[1] Q. Guo,et al. Small molecule modulators targeting protein kinase CK1 and CK2. , 2019, European journal of medicinal chemistry.
[2] P. Northcott,et al. Medulloblastoma , 2019, Nature Reviews Disease Primers.
[3] Jessica M. Rusert,et al. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma , 2018, Science Signaling.
[4] S. Khatua,et al. Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights , 2018, Current neuropharmacology.
[5] Jiyeon Kim,et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies , 2015, Front. Pharmacol..
[6] P. Northcott,et al. Molecular subgroups of medulloblastoma , 2012, Expert review of neurotherapeutics.
[7] M. Borad,et al. Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Adam Siddiqui-Jain,et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. , 2010, Cancer research.